Women Soldiers Respond to PTSD Therapy for Precipitating Event
February 28th 2007WHITE RIVER JUNCTION, Vt. -- For women soldiers being treated for post-traumatic stress disorder, symptoms improve when the therapy homes in on the original index event, no matter how long ago it occurred, researchers here found.
ASCO PROSTATE: Survival After Radiation Plus Androgen Mirrors Healthy Men
February 27th 2007KISSIMMEE, Fla. -- Radiation and androgen deprivation appears to bestow survival times for prostate cancer patients that are similar to the life expectancies of men of the same age who did not have cancer, researchers here reported.
ASCO PROSTATE: All Therapies for Early Prostate Cancer Don't Seem Equal
February 26th 2007KISSIMMEE, Fla., Feb. 26 -- For early prostate cancer, a five-year follow-up revealed that prostatectomy or brachytherapy had a small but statistically significant survival advantage over external-beam radiation in more than 2,300 patients.
ASCO PROSTATE: Potency Drugs Improve Sexual Function After Prostate Cancer Therapy
February 26th 2007KISSIMMEE, Fla. -- Prostate cancer patients taking sildenafil (Viagra) or its ilk reported improved sexual functioning and interest following radiation therapy and radical prostatectomy, researchers here reported.
ASCO PROSTATE: Satraplatin Plus Prednisone Slows Progression of Hormone Refractory Cancer
February 23rd 2007KISSIMMEE, Fla.- The investigational drug satraplatin, the first oral platinum-based agent, given with prednisone, significantly slowed the progression of hormone-refractory prostate cancer, albeit briefly, investigators said here today.
ASCO PROSTATE: Prostate Cancer Prevention Role Seen for BPH Drug
February 22nd 2007KISSIMMEE, Fla. -- Dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, may also prevent the development of prostate cancer by inducing genetic changes at the cellular level, researchers reported today.
ASCO PROSTATE: Men Reluctant to Chose Active Surveillance for Low Risk Prostate Cancer
February 22nd 2007KISSIMMEE, Fla. -- Only 9% of the men whose early prostate cancer was judged to be indolent agreed to active surveillance, an aggressive form of the so-called watchful waiting, urologists reported here today.